Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9688| Title: | Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. | Austin Authors: | Charles, Patrick G P ;Ward, Peter B;Johnson, Paul D R ;Howden, Benjamin P ;Grayson, M Lindsay | Affiliation: | Infectious Diseases | Issue Date: | 12-Jan-2004 | Publication information: | Clinical Infectious Diseases 2004; 38(3): 448-51 | Abstract: | We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/9688 | DOI: | 10.1086/381093 | ORCID: | Journal: | Clinical Infectious Diseases | URL: | https://pubmed.ncbi.nlm.nih.gov/14727222 | Type: | Journal Article | Subjects: | Anti-Bacterial Agents.pharmacology.therapeutic use Bacteremia.drug therapy.microbiology Drug Resistance, Bacterial Humans Methicillin Resistance Staphylococcal Infections.drug therapy.microbiology Staphylococcus aureus.drug effects Vancomycin.pharmacology.therapeutic use |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.